Carvedilol Modulates In‐Vitro Granulocyte‐Macrophage Colony‐Stimulating Factor‐Induced Interleukin‐10 Production in U937 Cells and Human Monocytes

References

• Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo‐controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997; 349(9049)375–380
   PubMed Web of Science ®Google Scholar
• Brizzi M. F., Aronica M. G., Rosso A., Bagnara G. P., Yarden Y., Pegoraro L. Granulocyte‐macrophage colony‐stimulating factor stimulates JAK2 signaling pathway and rapidly activates p93fes, STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes. J. Biol. Chem. 1996; 271(7)3562–3567
   Google Scholar
• Burgess A. W., Metcalf D. The nature and action of granulocyte‐macrophage colony stimulating factors. Blood 1980; 56(6)947–958
   Web of Science ®Google Scholar
• Bussolati B., Rollino C., Mariano F., Quarello F., Camussi G. IL‐10 stimulates production of platelet‐activating factor by monocytes of patients with active systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 2000; 122(3)471–476
   Google Scholar
• Capper E. A., Roshak A. K., Bolognese B. J., Podolin P. L., Smith T., Dewitt D. L., Anderson K. M., Marshall L. A. Modulation of human monocyte activities by tranilast, SB 252218, a compound demonstrating efficacy in restenosis. J. Pharmacol. Exp. Ther. 2000; 295(3)1061–1069
   Google Scholar
• Cicco N. A., Lindemann A., Content J., Vandenbussche P., Lubbert M., Causs J., Mertelsmann R., Herrmann F. Inducible production of interleukin‐6 by human polymorphonuclear neutrophil: role of granulocyte‐macrophage colony‐stimulating factor and tumor necrosis factor‐alpha. Blood 1990; 75(10)2049–2052
   Google Scholar
• de Waal Malefyt R., Abrams J., Bennett B., Figdor C. G., de Vries J. E. Interleukin 10 (IL‐10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL‐10 produced by monocytes. J. Exp. Med. 1991a; 174(5)1209–1220
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R., Haanen J., Spits H., Roncarolo M. G., te Velde A., Figdor C., Johnson K., Kastelein R., Yssel H., de Vries J. E. Interleukin‐10 (IL‐10) and viral IL‐10 strongly reduce antigen‐specific human T cell proliferation by diminishing the antigen‐presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 1991b; 174(4)915–924
   PubMed Web of Science ®Google Scholar
• Donnelly R. P., Dickensheets H., Finbloom D. S. The interleukin‐10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J. Interferon Cytokine Res. 1999; 19(6)563–573
   Web of Science ®Google Scholar
• Fiorentino D. F., Zlotnik A., Mosmann T. R., Howard M., O'Garra A. IL‐10 inhibits cytokine production by activated macrophages. J. Immunol. 1991a; 147(11)3815–3822
   PubMed Web of Science ®Google Scholar
• Fiorentino D. F., Zlotnik A., Vieira P., Mosmann T. R., Howard M., Moore K. W., O'Garra A. IL‐10 acts on the antigen‐presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 1991b; 146(10)3444–3451
   PubMed Web of Science ®Google Scholar
• Gazzinelli R. T., Oswald I. P., James S. L., Sher A. IL‐10 inhibits parasite killing and nitrogen oxide production by IFN‐gamma‐activated macrophages. J. Immunol. 1992; 148(6)1792–1796
   PubMed Web of Science ®Google Scholar
• Greenberger M. J., Strieter R. M., Kunkel S. L., Danforth J. M., Goodman R. E., Standiford T. J. Neutralization of IL‐10 increases survival in a murine model of Klebsiella pneumonia. J. Immunol. 1995; 155(2)722–729
   PubMed Web of Science ®Google Scholar
• Hansson G. K., Jonasson L., Seifert P. S., Stemme S. Immune mechanisms in atherosclerosis. Arteriosclerosis 1989; 9(5)567–578
   PubMedGoogle Scholar
• Hashimoto S. I., Komuro I., Yamada M., Akagawa K. S. IL‐10 inhibits granulocyte‐macrophae colony‐stimulating factor‐dependent human monocyte survival at the early stage of the culture and inhibits the generation of macrophages. J. Immunol. 2001; 167(7)3619–3625
   Google Scholar
• Ho L. J., Wang J. J., Shaio M. F., Kao C. L., Chang D. M., Han S. W., Lai J. H. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J. Immunol. 2001; 166(3)1499–1506
   PubMed Web of Science ®Google Scholar
• Howard M., O'Garra A., Ishida H., de Waal Malefyt R., de Vries J. Biological properties of interleukin 10. J. Clin. Immunol. 1992; 12(4)239–247
   PubMed Web of Science ®Google Scholar
• Larner A. C., David M., Feldman G. M., Igarashi K., Hackett R. H., Webb D. S., Sweitzer S. M., Petricoin E. F.D., Finbloom D. S. Tyrosine phosphorylation of DNA binding proteins by multiple cytokines [see comments]. Science 1993; 261(5129)1730–1733
   Google Scholar
• Lehmann M. H. Recombinant human granulocyte‐macrophage colony‐stimulating factor triggers interleukin‐10 expression in the monocytic cell line U937. Mol. Immunol. 1998; 35(8)479–485
   Google Scholar
• Lehmann M. H., Berg H. Interleukin‐10 expression is induced by increase of intracellular calcium levels in the monocytic cell line U937. Pflugers Arch.‐Eur. J. Physiol. 1998; 435: 868–870
   PubMed Web of Science ®Google Scholar
• Libby P., Hansson G. K. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab. Invest. 1991; 64(1)5–15
   PubMedGoogle Scholar
• Louis W. J., McNeil J. J., Workman B. S., Drummer O. H., Conway E. L. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. J. Cardiovasc. Pharmacol. 1987; 10(Suppl. 11)S89–S93
   Google Scholar
• Mallat Z., Heymes C., Ohan J., Faggin E., Lesèche G., Tedgui A. Expression of interleukin‐10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler. Thromb. Vasc. Biol. 1999; 19(3)611–616
   Google Scholar
• Matsuda Y., Akita H., Terashima M., Shiga N., Kanazawa K., Yokoyama M. Carvedilol improves endothelium‐dependent dilatation in patients with coronary artery disease. Am. Heart J. 2000; 140(5)753–759
   Google Scholar
• Metcalf D. The granulocyte‐macrophage colony‐stimulating factors. Science 1985; 229(4708)16–22
   Web of Science ®Google Scholar
• Miller B. A., Scaduto R. C., Jr., Tillotson D. L., Botti J. J., Cheung J. Y. Erythropoietin stimulates a rise in intracellular free calcium concentration in single early human erythroid precursors. J. Clin. Invest. 1988; 82(1)309–315
   Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983; 65(1–2)55–63
   PubMed Web of Science ®Google Scholar
• Mui A. L., Wakao H., O'Farrell A. M., Harada N., Miyajima A. Interleukin‐3, granulocyte‐macrophage colony‐stimulating factor and interleukin‐5 transduce signals through tow STAT5 homologs. EMBO J. 1995; 14(6)1166–1175
   Google Scholar
• Nelson S. Novel nonantibiotic therapies for pneumonia: cytokines and host defense. Chest 2001; 119(2 Suppl.)419S–425S
   Google Scholar
• Oberholzer A., Oberholzer C., Moldawer L. L. Interleukin‐10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti‐inflammatory drug. Crit. Care Med. 2002; 30(1 Supp.)S58–S63
   Google Scholar
• Parissis J. T., Adamopoulos S., Venetsanou K. F., Mentzikof D. G., Karas S. M., Kremastinos D. T. Clinical and neurohormonal correlates of circulating granulocyte‐macrophage colony‐stimulating factor in severe heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 2000; 86(6)707–710
   Google Scholar
• Pinderski Oslund L. J., Hedrick C. C., Olvera T., Hagenbaugh A., Territo M., Berliner J. A., Fyfe A. I. Interleukin‐10 blocks atherosclerotic events in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 1999; 19(12)2847–2853
   Google Scholar
• Plenz G., Koenig C., Severs N. J., Robenek H. Smooth muscle cells express granulocyte‐macrophage colony‐stimulating factor in the undiseased and atherosclerotic human coronary artery. Arterioscler. Thromb. Vasc. Biol. 1997; 17(11)2489–2499
   Google Scholar
• Rider P. M., Cushman M., Stampfer M. J., Tracy R. P., Hennekens C. H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 1997; 336(14)973–979
   Google Scholar
• Ross R. Atherosclerosis—an inflammatory disease. N. Engl. J. Med. 1999a; 340(2)115–126
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis is an inflammatory disease. Am. Heart J. 1999b; 138(5 Pt. 2)S419–S420
   PubMed Web of Science ®Google Scholar
• Ruffolo R. R., Jr., Feuerstein G. Z. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc. Drugs Ther. 1997; 11(Suppl. 1)247–256
   Google Scholar
• Seiler C., Pohl T., Wustmann K., Hutter D., Nicolet P. A., Windecker S., Eberli F. R., Meier B. Promotion of collateral growth by granulocyte‐macrophage colony‐stimulating factor in patients with coronary artery disease: a randomized, double‐blind, placebo‐controlled study. Circulation 2001; 104(17)2012–2017
   PubMed Web of Science ®Google Scholar
• Stasi R., Zinzani L., Galieni P., Lauta V. M., Damasio E., Dispensa E., Dammacco F., Tura S., Papa G. Detection of soluble interleukin‐2 receptor and interleukin‐10 in the serum of patients with aggressive non‐Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure. Cancer 1994; 74(6)1792–1800
   Google Scholar
• Terkeltaub R. A. IL‐10: an “immunologic scalpel” for atherosclerosis? Arterioscler. Thromb. Vasc. Biol. 1999; 19(12)2823–2825
   Google Scholar
• Ujihara M., Nomura K., Yamada O., Shibata N., Kobayashi M., Takano K. Granulocyte‐macrophage colony‐stimulating factor ensures macrophage survival and generation of the superoxide anion: a study using a monocytic‐differentiated HL60 subline. Free Radic. Biol. Med. 2001; 31(11)1396–1404
   Google Scholar
• Uyemura K., Demer L. L., Castle S. C., Jullien D., Berliner J. A., Gately M. K., Warrier R. R., Pham N., Fogelman A. M., Modlin R. L. Cross‐regulatory roles of interleukin (IL)‐12 and IL‐10 in atherosclerosis. J. Clin. Invest. 1996; 97(9)2130–2138
   PubMed Web of Science ®Google Scholar
• van der Does R., Hauf‐Zachariou U., Pfarr E., Holtbrugge W., Konig S., Griffiths M., Lahiri A. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. Am. J. Cardiol. 1999; 83(5)643–649
   PubMed Web of Science ®Google Scholar
• Wakkach A., Cottrez F., Groux H. Can interleukin‐10 be used as a true immunoregulatory cytokine?. Eur. Cytokine Netw. 2000; 11(2)153–160
   PubMed Web of Science ®Google Scholar
• Wang J., Wang S., Lu Y., Weng Y., Gown A. M. GM‐CSF and M‐CSF expression is associated with macrophage proliferation in progressing and regressing rabbit atheromatous lesions. Exp. Mol. Pathol. 1994; 61(2)109–118
   Google Scholar
• Wanidworanun C., Strober W. Predominant role of tumor necrosis factor‐alpha in human monocyte IL‐10 synthesis. J. Immunol. 1993; 151(12)6853–6861
   Google Scholar
• Yue T. L., Mckenna P. J., Lysko P. G., Gu J. L., Lysko K. A., Ruffolo R. R., Jr., Feuerstein G. Z. SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant. Eur. J. Pharmacol. 1994; 251(2,3)237–243
   Google Scholar